Cheng-Yang Chou

National Cheng Kung University Hospital

Papers

1

Total Citations

10

H-Index

1

About

Cheng-Yang Chou is a leading clinical researcher in gynecologic oncology, with a particular focus on ovarian, tubal, and peritoneal cancers. His most prominent work, the ROBOT study (2020), provides critical real-world evidence on the long-term efficacy and safety of adding bevacizumab to chemotherapy in Asian patients. This eight-year retrospective analysis, cited 10 times, offers invaluable insights into prognostic impacts and adverse effects beyond controlled clinical trials, directly informing treatment strategies for a population often underrepresented in global research. Chou’s contributions bridge the gap between trial data and clinical practice, helping to optimize front-line and relapse therapy for these challenging malignancies. His work is essential reading for oncologists and researchers seeking to understand the nuanced, long-term outcomes of targeted therapies in diverse patient cohorts.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
10 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: National Cheng Kung University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago